Abstract:Objective To investigate the possibility of using melanoma antigen-1 (MAGE-1) peptide as a tumor vaccine to treat hepatocellular carcinoma ( HCC).Methods The expressions of MAGE-1 in 8 HCC cell lines and in liver cancer tissue from a patient were detected using RT-PCR. The type of human leucocyte antigen I (HLA I) of both 8 HCC cell lines and peripheral blood mononuclear cells of the patient was detected using a microcytotoxicity method to screen out target cell lines for the cytotoxicity assay. Peripheral blood mononuclear cells from the HCC patient pulsed with an MAGE-1 pepticle ( NYKCRFPEI) were used as antigen presenting cells. Autogenous peripheral blood mononuclear cells were stimulated with antigen presenting cells every 7 days for 4 times to elicit cytotoxic T lymphocytes. The phenotype of effector cells was analyzed using flow cytometry. The cytotoxicity of effector cells was detected with a lactate dehydrogenase releasing assay.Results The expressions of both MAGE-1 and HLA-A24 were detected in BEL7405 cell line which were used as the positive target cell line in the cytotoxicity assay. The expression of MAGE-1 alone was detected in HLE, BEL7402, BEL7404, QGY7703 and SMMC7721 cell lines, and the expression of neither MAGE-1 nor HLA-A24 was shown in QGY 7701 and HpG2 cell lines. The last 7 cell lines could be used as negative target cell lines in the cytotoxicity assay. Peripheral blood mononuclear cells expanded 32 folds during 28-day culture. The ratio of CD3(+) T cells increased by 16% (from 54% to 70%), and the ratio of CD8(+) T cells increased by 20% (from 36% to 56%) during 28-day culture. When the ratio of effector cells to target cells was 10: 1, effector cells exhibited 62.5% cytotoxicity against autogenous lymphoblasts pulsed with the peptide (NYKCRFPEI) of MAGE-1 antigen, 40.25% cytotoxicity against BEL7405 cells, compared with 17.88% cytolysis observed against autogenous lymphoblasts, 19.55% against HLE cells, and 1.6% against QGY7701 cells. When the ratio of effector cells to target cells was 3. 3:1, the cytotoxicity of effector cells against the peptide pulsed autogenous lymphoblasts was 53.6%, which was much higher against autogenous lymphoblasts, HLE cells and QGY7701 cells at 15.6%, 13% and 1%, respectively.Conclusion The results demonstrate that cytotoxic T lymphocytes with the ability to specifically lyse target cells expressing both MAGE-1 and HLA-A24 could be successfully induced by the MAGE-1 peptide NYKCRFPEI in vitro. This indicates that a good result might be anticipated if this peptide is used as a tumor vaccine to treat HLA-A24 HCC patients.

Induction of tumor specific cytotoxic T lymphocytes from human peripheral blood by stimulation with MHC-I matched allogenic renal cell carcinoma

Protective Immunity Transferred by Infusion of Cytomegalovirus-Specific CD8(+) T Cells Within Donor Grafts: Its Associations with Cytomegalovirus Reactivation Following Unmanipulated Allogeneic Hematopoietic Stem Cell Transplantation.

Rerovirus Mediated Hsv-Tk Gene Transfer Can Influence The Function Of Human T-Lymphocyte

Induction of Cytotoxic T Lymphocytes from the Peripheral Blood of a Hepatocellular Carcinoma Patient Using a MAGE-1 Peptide (NYKCRFPEI) in Vitro

Induction of Cytotoxic T-Lymphocytes Specific for Malignant Glioma by Hla Dimer-Based Artificial Antigen-Presenting Cells

NK and T cells with a cytotoxic/migratory phenotype accumulate in peritumoral tissue of patients with clear cell renal carcinoma

Raising Allo-Restricted Cytotoxic T Lymphocytes by Co-Culture of Murine Splenocytes with Autologous Macrophage Bearing the Peptide/allo–major Histococompatibility Complex

Cardiac Allograft Tolerance Induced by Isogeneic CD4+CD25+ Regulatory T Cells.

Cytotoxic Effect of TGF-β Insensitive Dendritic Cell Vaccine on Cytotoxic T Lymphocytes in Mice with Renal Cell Carcinoma

Induction of Cytotoxic T Lymphocytes from the Hepatocellular Carcinoma Patients by Using MAGE-3- Gene-Derived and HLA-A2-restricted Peptide

Immunotherapy for Human Renal Cell Carcinoma by Adoptive Transfer of Autologous Transforming Growth Factor Beta-Insensitive CD8(+) T Cells

Heterogeneous expansion of CD4+ tumor-infiltrating T-lymphocytes in clear cell renal cell carcinomas

Induction of cytotoxic T lymphocytes specific to malignant glioma using T2 cells pulsed with HLA-A2-restricted interleukin-13 receptor α2 peptide in vitro

Allo-Restricted Ctls Generated By Coculturing Of Pbls And Autologous Monocytes Loaded With Allogeneic Peptide/Hla/Igg1-Fc Fusion Protein

Induction of Cytotoxic T Lymphocytes from the Peripheral Blood of A Hepatocellular Carcinoma Patient Using Melanoma Antigen-1 (Mage-1) Peptide

Allogeneic Dendritic Cells Induce Potent Antitumor Immunity by Activating KLRG1+CD8 T Cells

Application of T Cell Vaccine to Clinical Renal Transplantation

[Cytomegalovirus-Specific T Cells Immune Reconstitution after Human Leukocyte Antigen Matched Sibling Donor Allogeneic Bone Marrow Plus Peripheral Blood Hematopoietic Stem Cell Transplantation].

Mechanism of cytotoxicity mediated by autologous tumour-specific CD4~+ T-cell clones against B-cell non-Hodgkin's lymphoma

Peptide Derived from MAGE-3 Epitope Induced Cytotoxic T Lymphocytes of Hepatocellular Carcinoma Patient in Vitro

Adoptive Transfer of Tumor-Reactive Transforming Growth Factor-β–Insensitive Cytolytic T Cells for Treatment of Established Mouse Renca Tumors